Merck’s Lipfendra Becomes First FDA-Approved Oral PCSK9 Inhibitor for High Cholesterol

Oral cholesterol therapy offers an alternative to injectable PCSK9 inhibitors as Merck targets multi-billion-dollar cardiovascular market. Merck & Co. (MSD) has secured US Food and Drug Administration (FDA) approval for Lipfendra (enlicitide), making it the first once-daily oral PCSK9 inhibitor approved in the US for lowering low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia (HeFH).

The approval marks a significant milestone in the cholesterol treatment landscape, introducing an oral alternative to injectable PCSK9 inhibitors that have transformed LDL-C management over the past decade.

First Oral PCSK9 Inhibitor Approved in the US

Lipfendra is indicated for adults with hypercholesterolaemia, including patients with HeFH, and works by inhibiting PCSK9, a protein involved in regulating LDL cholesterol levels.

Unlike existing PCSK9 therapies, which require injections every two weeks or monthly, Lipfendra is administered as a once-daily tablet, potentially offering greater convenience for patients and expanding access to this class of cholesterol-lowering medicines.

Dean Y. Li, President of Merck Research Laboratories, described the approval as a pivotal moment, saying the drug provides patients with an important new treatment option.

Phase III Trials Demonstrated Significant LDL-C Reduction

The FDA approval was supported by data from two Phase III clinical trials:

• CORALreef Lipids

• CORALreef HeFH
  

In the CORALreef HeFH study, Lipfendra achieved approximately 59% LDL-C reduction versus placebo in patients with heterozygous familial hypercholesterolaemia.

Meanwhile, the CORALreef Lipids trial demonstrated an almost 56% reduction in LDL-C among patients with atherosclerotic cardiovascular disease (ASCVD).

Merck is also conducting a cardiovascular outcomes study to determine whether LDL-C reductions translate into lower rates of heart attacks, strokes and cardiovascular death.

Challenging the Injectable PCSK9 Market

The PCSK9 inhibitor market has traditionally been dominated by injectable biologics, including:

• Amgen's Repatha (evolocumab)

• Sanofi and Regeneron's Praluent (alirocumab)
  

While these medicines have demonstrated strong efficacy, injectable administration has been viewed as a barrier for some patients.

Lipfendra's oral formulation could broaden use of PCSK9 inhibition, particularly within primary care settings where physicians may favour a tablet over injectable therapy.

Pricing also appears central to Merck's commercial strategy.

Lipfendra will launch with a list price of approximately $315 per month, substantially below the typical $500–600 monthly cost of existing injectable PCSK9 inhibitors.

Analysts believe this pricing strategy could accelerate adoption and expand the overall market rather than simply compete for existing patients.

Strategic Importance for Merck

Lipfendra represents one of Merck's most important late-stage pipeline assets as the company prepares for the eventual loss of exclusivity of blockbuster immunotherapy Keytruda (pembrolizumab) in 2028.

The company has identified several pipeline medicines expected to drive future growth, with Lipfendra viewed as a potential multi-billion-dollar product.

Analysts suggest that widespread uptake among primary care physicians could generate peak annual sales approaching $5bn, particularly if oral therapy encourages earlier use of PCSK9 inhibition in cholesterol management.

Competition Continues to Build

Although Lipfendra is the first oral PCSK9 inhibitor to reach the market, competition is already emerging.

AstraZeneca is developing AZD0780, an investigational oral PCSK9 inhibitor that has demonstrated nearly 51% LDL-C reduction in mid-stage studies.

One potential differentiator may be dosing convenience. Lipfendra must be taken on an empty stomach, with patients required to wait at least 30 minutes before eating, while AstraZeneca's candidate has not demonstrated the same fasting requirement.

As oral PCSK9 therapies enter clinical practice, convenience, pricing and long-term cardiovascular outcomes are likely to become key differentiators.

Outlook

The approval of Lipfendra introduces the first oral PCSK9 inhibitor into clinical practice and could reshape the treatment landscape for patients requiring intensive LDL-C lowering.

By combining efficacy comparable to injectable therapies with oral administration and competitive pricing, Merck is positioning Lipfendra to expand adoption of PCSK9 inhibition beyond specialist care.

With cardiovascular outcomes data still to come and additional oral competitors in development, the approval represents the beginning of a new phase in cholesterol management rather than the end of the story.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com